Cara Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
TVRD$1.41+47.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| · December 31, 2023 · December 31, 2022 | ||||||
| Assets · · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $51,775 | | $63,741 | ||
| Marketable securities | | 48,983 | | 81,658 | ||
| Accounts receivable, net - related party | | | 2,765 | | | 3,260 |
| Inventory, net | | | 2,821 | | | 2,383 |
| Income tax receivable | | 697 | | 697 | ||
| Other receivables | | 555 | | 496 | ||
| Prepaid expenses | | 8,154 | | 16,267 | ||
| Restricted cash | | 408 | | 408 | ||
| Total current assets | | 116,158 | | 168,910 | ||
| Operating lease right-of-use assets | | | 4,864 | | | 1,551 |
| Marketable securities, non-current | | — | | 11,350 | ||
| Property and equipment, net | | 3,322 | | 426 | ||
| Restricted cash, non-current | | 1,500 | | — | ||
| Total assets | | $125,844 | | $182,237 | ||
| Liabilities and stockholders’ equity | | | | |||
| Current liabilities: | | | | |||
| Accounts payable and accrued expenses | | $25,592 | | $21,540 | ||
| Operating lease liabilities, current | | — | | 1,918 | ||
| Total current liabilities | | 25,592 | | 23,458 | ||
| | | | | | | |
| Liability related to sales of future royalties and milestones, net | | | 37,079 | | | — |
| Operating lease liabilities, non-current | | | 6,088 | | | — |
| Total liabilities | | 68,759 | | 23,458 | ||
| Commitments and contingencies (Note 19) | | — | | — | ||
| Stockholders’ equity: | | | | |||
| Preferred stock; $0.001 par value; 5,000,000 shares authorized at December 31, 2023 and December 31, 2022, zero shares issued and outstanding at December 31, 2023 and December 31, 2022 | | — | | — | ||
| Common stock; $0.001 par value; 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, 54,480,704 shares and 53,797,341 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | | 54 | | 53 | ||
| Additional paid-in capital | | 742,036 | | 726,630 | ||
| Accumulated deficit | | (684,745) | | (566,232) | ||
| Accumulated other comprehensive loss | | (260) | | (1,672) | ||
| Total stockholders’ equity | | 57,085 | | 158,779 | ||
| Total liabilities and stockholders’ equity | | $125,844 | | $182,237 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.